Everything tagged "value" across research, earnings, and macro.
198 articles
Sterling Infrastructure has transformed into a higher-quality infrastructure compounder, led by explosive E-Infrastructure growth and a backlog that keeps outrunning the plan. The stock still screens expensive, but the operating momentum is strong enough to support a Buy.
ASML’s EUV leadership and growing installed-base revenue support a strong long-term thesis, but the stock still trades at demanding multiples. The report stays constructive with a Buy rating, while flagging valuation as the main risk.
Lam Research is benefiting from AI-led demand in deposition, etch, and clean tools, with record revenue, expanding margins, and a growing installed-base services business. Valuation is rich, but the company’s operating leverage and memory/foundry exposure keep the stock attractive for disciplined buyers.
Vertex combines a dominant cystic fibrosis franchise with early diversification in rare disease and acute pain. The stock looks like a disciplined Buy, but valuation still depends on execution across ALYFTREK, CASGEVY, JOURNAVX, and the renal pipeline.
S&P Global combines recurring data, ratings, and index revenue with strong AI product adoption and elite margins. The stock looks attractive on pullbacks, but valuation keeps the upside measured.
AstraZeneca combines durable large-cap biopharma scale with broad-based growth across oncology, rare disease, and respiratory. The report rates AZN a Buy, with valuation the main debate and fair value anchored at $215.
Lindsay Corporation is a niche irrigation and road-safety industrial with a strong balance sheet, but near-term demand softness and lumpy project comparisons keep the stock near fair value.
Mueller Industries combines exceptional balance sheet strength with durable profitability and growing exposure to HVAC and industrial infrastructure. The stock looks high quality, but valuation keeps the call at Hold with upside better suited to pullbacks.
AT&T is a Buy for investors seeking a defensive telecom with improving fiber economics, stable wireless growth, and a valuation that still looks discounted. Q1 2026 showed stronger revenue, EBITDA, and EPS, while the company continues to convert network investment into customer gains.
Copart remains a high-quality compounder with elite margins, a fortress balance sheet, and durable international growth levers. Near-term revenue growth has slowed, but the stock still screens as a Buy on valuation and cash generation.
Martin Marietta delivered a strong Q1 with record aggregates shipments and reaffirmed 2026 guidance, but the stock still trades at a premium multiple. The report argues the company’s quarry moat and portfolio shift support a Buy, though valuation leaves less room for error.
Verizon is showing a real operating inflection, with 1Q26 revenue and EPS growth, improving churn, and first-quarter postpaid phone net adds that support the turnaround case. The stock still screens as a value-backed income play, but heavy leverage keeps the risk profile intact.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator